Novel insights into contact dermatitis
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 718 KB, PDF-dokument
Contact dermatitis is a common disease that is caused by repeated skin contact with contact allergens or irritants, resulting in allergic contact dermatitis (ACD) and/or irritant contact dermatitis. Attempts have been made to identify biomarkers to distinguish irritant and allergic patch test reactions, which could aid diagnosis. Some promising candidates have recently been identified, but verification and validation in clinical cases still need to be done. New causes of ACD are constantly being recognized. In this review, 10 new contact allergens from recent years, several relating to anti-aging products, have been identified. Frequent allergens causing considerable morbidity in the population, such as the preservative methylisothiazolinone, have been regulated in the European Union. A significant drop in the number of cases has been seen, whereas high rates are still occurring in other areas such as North America. Other frequent causes are fragrance allergens, especially the widely used terpenes and acrylates found in medical devices for control of diabetes. These represent unsolved problems. Recent advances in immunology have opened the way for a better understanding of the complexity of contact dermatitis, especially ACD—a disease that may be more heterogenous that previous understood, with several subtypes. With the rapidly evolving molecular understanding of ACD, the potential for development of new drugs for personalized treatment of contact dermatitis is considerable.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Journal of Allergy and Clinical Immunology |
| Vol/bind | 149 |
| Udgave nummer | 4 |
| Sider (fra-til) | 1162-1171 |
| Antal sider | 10 |
| ISSN | 0091-6749 |
| DOI | |
| Status | Udgivet - 2022 |
Bibliografisk note
Funding Information:
The authors have received support for other research activities from the European Union research fund DG Employment, Social Affairs and Inclusion (grant VS/2019/0040 [to J.D.G. and W.U.]), the Danish Environmental Protection Agency to (J.D.G.), and the Leo Foundation (to J.D.G. and C.B.).
Funding Information:
The authors have received support for other research activities from the European Union research fund DG Employment, Social Affairs and Inclusion (grant VS/2019/0040 [to J.D.G. and W.U.]), the Danish Environmental Protection Agency to (J.D.G.), and the Leo Foundation (to J.D.G. and C.B.). Disclosure of potential conflicts of interest: J. F. B. Schwensen is president elect of the European Contact Dermatitis Society, is chair of the Cosmetic Council, serves as an advisor to the Ministry of Environment (unpaid), and has received personal fees from Galderma Nordic AB outside submitted work. J. P. Thyssen reports being an advisor for AbbVie, Almirall, Arena Pharmaceuticals, Coloplast, OM Pharma, Aslan Pharmaceuticals, Union Therapeutics, Eli Lilly and Company, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme; being a speaker for AbbVie, Almirall, Eli Lilly and Company, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme; receiving research grants from Pfizer, Regeneron, and Sanofi-Genzyme; and doing medical writing as part of coauthorships for AbbVie, Pfizer, Eli Lilly, Regeneron, Sanofi-Genzyme and LEO Pharma. W. Uter reports participating in the EFISS study of the IDEA project (IFRA-funded [grant agreement; no funds received yet], receiving indemnities as an external expert of the Scientific Committee on Consumer Safety of the European Commission (personal income), receiving personal travel reimbursement for participation in the IDEA project surveillance study, and being a data safety and monitoring board member for a T-cell vaccination study in uveal melanoma (no fees received). The remaining authors declare that they have no relevant conflicts of interest.
Publisher Copyright:
© 2022 American Academy of Allergy, Asthma & Immunology
ID: 305717344